{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:58Z","timestamp":1781650798775,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15989-1","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:03:45Z","timestamp":1777097025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8909-5709","authenticated-orcid":false,"given":"Teppei","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"15989_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"15989_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627.","journal-title":"N Engl J Med"},{"key":"15989_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N. Engl. J Med. 2015;373:1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"J Med"},{"key":"15989_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"J Med"},{"key":"15989_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet"},{"key":"15989_CR6","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"15989_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1440-1843.2009.01547.x","volume":"14","author":"Y Ozawa","year":"2009","unstructured":"Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14:723\u20138. https:\/\/doi.org\/10.1111\/j.1440-1843.2009.01547.x.","journal-title":"Respirology"},{"key":"15989_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","volume":"147","author":"S Tomassetti","year":"2015","unstructured":"Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157\u201364. https:\/\/doi.org\/10.1378\/chest.14-0359.","journal-title":"Chest"},{"key":"15989_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2017.03.016","volume":"45","author":"T Karampitsakos","year":"2017","unstructured":"Karampitsakos T, Tzilas V, Tringidou R, Steiropoulos P, Aidinis V, Papiris SA, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;45:1\u201310. https:\/\/doi.org\/10.1016\/j.pupt.2017.03.016.","journal-title":"Pulm Pharmacol Ther"},{"key":"15989_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.athoracsur.2015.03.094","volume":"100","author":"T Omori","year":"2015","unstructured":"Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K, et al. Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg. 2015;100:954\u201360. https:\/\/doi.org\/10.1016\/j.athoracsur.2015.03.094.","journal-title":"Ann Thorac Surg"},{"key":"15989_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00432-016-2199-z","volume":"142","author":"N Kanaji","year":"2016","unstructured":"Kanaji N, Tadokoro A, Kita N, Murota M, Ishii T, Takagi T, et al. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. J Cancer Res Clin Oncol. 2016;142:1855\u201365. https:\/\/doi.org\/10.1007\/s00432-016-2199-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"15989_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723\u201333. https:\/\/doi.org\/10.1200\/JCO.20.01605.","journal-title":"J Clin Oncol"},{"key":"15989_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7.","journal-title":"Lancet"},{"key":"15989_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","volume":"134","author":"D Fujimoto","year":"2019","unstructured":"Fujimoto D, Yomota M, Sekine A, Morita M, Morimoto T, Hosomi Y, et al. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. Lung Cancer. 2019;134:274\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.001.","journal-title":"Lung Cancer"},{"key":"15989_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","volume":"125","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer. 2018;125:212\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.001.","journal-title":"Lung Cancer"},{"key":"15989_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9:847\u201355. https:\/\/doi.org\/10.1111\/1759-7714.12759.","journal-title":"Thorac Cancer"},{"key":"15989_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"15989_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","volume":"15","author":"S Ikeda","year":"2020","unstructured":"Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y, et al. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. J Thorac Oncol. 2020;15:1935\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.018.","journal-title":"J Thorac Oncol"},{"key":"15989_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","volume":"119","author":"D Fujimoto","year":"2018","unstructured":"Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018;119:14\u201320. https:\/\/doi.org\/10.1016\/j.lungcan.2018.02.017.","journal-title":"Lung Cancer"},{"key":"15989_CR20","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: A prospective cohort study. J Thorac Oncol. 2017;12:1798\u2013805. https:\/\/doi.org\/10.1016\/j.jtho.2017.08.022.","journal-title":"J Thorac Oncol"},{"key":"15989_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018;4:374\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925.","journal-title":"JAMA Oncol"},{"key":"15989_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdw640.","journal-title":"Ann Oncol"},{"key":"15989_CR23","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/1759-7714.13187","volume":"10","author":"M Tone","year":"2019","unstructured":"Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T, et al. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer. 2019;10:2006\u201312. https:\/\/doi.org\/10.1111\/1759-7714.13187.","journal-title":"Thorac Cancer"},{"key":"15989_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","volume":"14","author":"K Suresh","year":"2019","unstructured":"Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 2019;14:494\u2013502. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.016.","journal-title":"J Thorac Oncol"},{"key":"15989_CR25","doi-asserted-by":"publisher","first-page":"e001342","DOI":"10.1136\/bmjresp-2022-001342","volume":"10","author":"A Davis","year":"2023","unstructured":"Davis A, Johnson DB, Bastarache JA. Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis. BMJ Open Respir Res. 2023;10:e001342. https:\/\/doi.org\/10.1136\/bmjresp-2022-001342.","journal-title":"BMJ Open Respir Res"},{"key":"15989_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","volume":"20","author":"J Fukihara","year":"2019","unstructured":"Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors, Clin. Lung Cancer. 2019;20:442\u2013e4504. https:\/\/doi.org\/10.1016\/j.cllc.2019.07.006.","journal-title":"Lung Cancer"},{"key":"15989_CR27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3892\/etm.2012.714","volume":"4","author":"S Ozkaya","year":"2012","unstructured":"Ozkaya S, Findik S, Dirican A, Atici AG. Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med. 2012;4:1035\u20138. https:\/\/doi.org\/10.3892\/etm.2012.714.","journal-title":"Exp Ther Med"},{"key":"15989_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2009.03.014","volume":"67","author":"K Kaira","year":"2010","unstructured":"Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer. 2010;67:120\u20133. https:\/\/doi.org\/10.1016\/j.lungcan.2009.03.014.","journal-title":"Lung Cancer"},{"key":"15989_CR29","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/cncr.24871","volume":"116","author":"T Wang","year":"2010","unstructured":"Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 2010;116:1518\u201325. https:\/\/doi.org\/10.1002\/cncr.24871.","journal-title":"Cancer"},{"key":"15989_CR30","doi-asserted-by":"publisher","first-page":"1348034","DOI":"10.3389\/fimmu.2024.1348034","volume":"15","author":"S Takei","year":"2024","unstructured":"Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, et al. Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS\u2009\u2265\u200950. Front Immunol. 2024;15:1348034. https:\/\/doi.org\/10.3389\/fimmu.2024.1348034.","journal-title":"Front Immunol"},{"key":"15989_CR31","doi-asserted-by":"publisher","first-page":"103117","DOI":"10.18632\/oncotarget.21602","volume":"8","author":"Y Oya","year":"2017","unstructured":"Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget. 2017;8:103117\u201328. https:\/\/doi.org\/10.18632\/oncotarget.21602.","journal-title":"Oncotarget"},{"key":"15989_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","volume":"11","author":"MA Socinski","year":"2016","unstructured":"Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, et al. Clinicopathologic features of advanced squamous NSCLC. J Thorac Oncol. 2016;11:1411\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2016.05.024.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15989-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15989-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15989-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:42:37Z","timestamp":1781649757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15989-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15989"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15989-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of Aichi Cancer Center Hospital approved this protocol (approval number: 2025-0-249). This study was conducted in accordance with the Good Clinical Practice guidelines and the guiding principles of the Declaration of Helsinki and its later amendments, as well as applicable local laws and regulations. In this retrospective study, the need for informed consent was waived according to the \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects.\u201d The summary of this research protocol was posted on the website of Aichi Cancer Center Hospital, and the participants were provided with the opportunity to opt out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Teppei Yamaguchi reported receiving personal fees from AstraZeneca, Novartis Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Pfizer, Taiho Pharmaceutical, and Merck Sharp & Dohme. Junichi Shimizu reported receiving honoraria from Novartis, Daiichi Sankyo, Chugai, Taiho, Merck Sharp & Dohme, AstraZeneca, Merck Biopharma, Takeda, Pfizer, Amgen, and Ono Pharmaceutical. Reiko Matsuzawa reported receiving honoraria from Merck Sharp & Dohme, Chugai, Bristol Myers Squibb, Ono Pharmaceutical, Takeda, Taiho, AstraZeneca, Daiichi Sankyo, and Novartis. Yutaka Fujiwara reported receiving research funding from Abbvie, AnHeart, Astellas, Bristol Myers Squibb, Eli Lilly, Merck KGaA, Novocure, Taiho Pharmaceutical, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai, Incyte, Merck Sharp & Dohme, and Shanghai Junshi; honoraria from AstraZeneca, Amgen, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Novocure, Ono Pharmaceutical, Pfizer, Takeda, and Taiho Pharmaceutical; and participation on advisory boards for AstraZeneca, Chiome Bioscience, Daiichi Sankyo, Micron, Nippon Kayaku, and Ono Pharmaceutical. All other authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"735"}}